-transparent.png){kind=logo}
Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination. No increase in tissue reactions or adverse side-effects (apart from a readily reversible leukopenia) was observed. The implication is that razoxane acts as a well tolerated adjuvant for radiotherapy.
Related Publications
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
January 1978,
International journal of radiation oncology, biology, physics,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
March 1980,
The British journal of dermatology,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
December 1976,
Lancet (London, England),
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
January 1978,
Strahlentherapie. Sonderbande,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
January 1978,
International journal of radiation oncology, biology, physics,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
January 1978,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
May 2009,
International journal of radiation oncology, biology, physics,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
December 1996,
International journal of radiation oncology, biology, physics,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
January 1982,
Cancer chemotherapy and pharmacology,
K Hellmann, and
R D Ryall, and
E Macdonald, and
K A Newton, and
S E James, and
S Jones
January 1979,
Cancer treatment reports,
